Analysts Set Inspire Medical Systems, Inc. (NYSE:INSP) Price Target at $81.26

Inspire Medical Systems, Inc. (NYSE:INSP) has been given an average recommendation of “Hold” by the twenty-one brokerages that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $81.2632.

Several analysts recently commented on the stock. Summit Redstone set a $39.00 price objective on shares of Inspire Medical Systems in a research report on Friday, May 22nd. Truist Financial lifted their target price on shares of Inspire Medical Systems from $50.00 to $54.00 and gave the stock a “hold” rating in a report on Thursday, July 16th. Weiss Ratings downgraded shares of Inspire Medical Systems from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, May 6th. Stifel Nicolaus cut their price target on shares of Inspire Medical Systems from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Tuesday, May 5th. Finally, Freedom Capital raised shares of Inspire Medical Systems to a “strong-buy” rating in a research report on Tuesday, June 30th.

Inspire Medical Systems Stock Performance

Shares of NYSE INSP opened at $53.35 on Friday. The company has a 50 day simple moving average of $44.55 and a two-hundred day simple moving average of $58.28. Inspire Medical Systems has a fifty-two week low of $38.91 and a fifty-two week high of $147.03. The company has a market capitalization of $1.54 billion, a price-to-earnings ratio of 11.88, a P/E/G ratio of 5.12 and a beta of 0.71.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings results on Monday, May 4th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.38. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.The firm had revenue of $204.58 million for the quarter, compared to analysts’ expectations of $200.04 million. During the same period in the previous year, the firm posted $0.10 EPS. The business’s revenue for the quarter was up 1.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, analysts forecast that Inspire Medical Systems will post 0.93 earnings per share for the current fiscal year.

Institutional Trading of Inspire Medical Systems

Several institutional investors have recently added to or reduced their stakes in the business. CWM LLC lifted its holdings in shares of Inspire Medical Systems by 216.1% during the fourth quarter. CWM LLC now owns 354 shares of the company’s stock valued at $33,000 after purchasing an additional 242 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in Inspire Medical Systems by 1,115.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company’s stock worth $33,000 after buying an additional 580 shares in the last quarter. Havemeyer Place LP bought a new stake in Inspire Medical Systems in the 4th quarter worth about $39,000. V Square Quantitative Management LLC purchased a new position in Inspire Medical Systems in the 4th quarter worth about $40,000. Finally, Smartleaf Asset Management LLC raised its position in Inspire Medical Systems by 84.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock worth $42,000 after buying an additional 205 shares during the last quarter. 94.91% of the stock is currently owned by hedge funds and other institutional investors.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.